Testing requirements are likely slowing biosimilar entries in the US

Testing requirements are likely slowing biosimilar entries in the US

Source: 
RAPS.org
snippet: 

Biosimilars have been slow to enter the US market for complex reasons ranging from the manipulation of patent protections to brand-name drug rebates. Now a new analysis, published in the Mayo Clinic Proceedings, suggests that a “high testing bar” for biosimilars to gain regulatory approval is another contributing factor.